News for Healthier Living

How the Novel Antibody Felzartamab Impacts IgA Nephropathy

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients' kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab's potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23- 27.

October 25, 2024


October 31 2024

October 30 2024

October 29 2024

October 28 2024

October 27 2024

October 26 2024

October 25 2024

October 24 2024

October 23 2024

October 22 2024

October 21 2024

October 20 2024

October 19 2024

October 18 2024

October 17 2024